Department of Neurology, Memory Research Resource Center for Alzheimer's Disease, University Hospital of Montpellier, 80 Rue Augustin Fliche, Montpellier Cedex 05, France.
J Clin Neurophysiol. 2011 Dec;28(6):625-32. doi: 10.1097/WNP.0b013e31823cc2d3.
This study was designed to evaluate the predictive value of event-related potential (ERP; N2 and P3b) in patients with mild cognitive impairment (MCI). Seventy-one patients with MCI were selected and compared with 31 healthy control subjects. They benefited from an initial assessment that included a neuropsychological evaluation and ERP. We followed them up for 1 year, and during their last visit, they benefited again from ERP and neuropsychological tests. At the end of the study, 2 subgroups of patients with MCI were differentiated according to their clinical evolution from baseline to follow-up: 41 MCI progressors (MCI-P) and 30 MCI nonprogressors (MCI-non P). The MCI-P patients had a significant decline in their executive functions compared with the MCI-non-P group at baseline and follow-up especially on trail making test B (TMT B) and verbal fluency (P < 0.0001). At baseline, MCI-P had increased P3b latencies and low P3b amplitudes compared with MCI-non P. The MCI-P showed an inversion of the P3b rostrocaudal gradient with a significant decrease in the amplitude of P3b in the parietal area compared with the MCI-non P. At follow-up, 17 MCI-P patients had converted to Alzheimer's disease (AD). There was a significant rate of decline of the amplitude of N2 and P3b in the frontal area among the groups. Furthermore, the MCI-P had a higher decrease in the rostrocaudal gradient of P3b and prolonged N2 and P3b latencies than the MCI-non P did. The sensitivity and specificity were approximately 80% and 70%, using P3b amplitude to discriminate the MCI-P from the MCI-non P. Our study underlines the interest of using N2 and P3b as neurophysiological markers for measuring MCI decline progression.
这项研究旨在评估事件相关电位(ERP;N2 和 P3b)在轻度认知障碍(MCI)患者中的预测价值。选择了 71 名 MCI 患者,并与 31 名健康对照者进行比较。他们受益于初始评估,包括神经心理学评估和 ERP。我们对他们进行了为期 1 年的随访,在最后一次就诊时,他们再次接受了 ERP 和神经心理学测试。在研究结束时,根据患者从基线到随访的临床演变,将 MCI 患者分为 2 个亚组:41 名 MCI 进展者(MCI-P)和 30 名 MCI 非进展者(MCI-non P)。与 MCI-non P 组相比,MCI-P 患者在基线和随访时的执行功能明显下降,尤其是在连线测试 B(TMT B)和言语流畅性上(P<0.0001)。在基线时,与 MCI-non P 相比,MCI-P 的 P3b 潜伏期延长,P3b 振幅降低。MCI-P 表现出 P3b 额-尾梯度的反转,与 MCI-non P 相比,顶区 P3b 振幅显著降低。在随访时,17 名 MCI-P 患者已转化为阿尔茨海默病(AD)。各组中 N2 和 P3b 的振幅均有明显下降。此外,与 MCI-non P 相比,MCI-P 的 P3b 额-尾梯度下降更大,N2 和 P3b 潜伏期延长。使用 P3b 振幅区分 MCI-P 和 MCI-non P,其敏感性和特异性分别约为 80%和 70%。我们的研究强调了使用 N2 和 P3b 作为神经生理学标志物来衡量 MCI 进展的意义。